Sample Report, 550960
Patient ID:
Specimen ID: **324-988-9005-0**

DOB: **01/01/1992**
Age: **32**
Sex: **Male**

Patient Report
Account Number: **90000999**
Ordering Physician:

labcorp

Date Collected: **11/19/2024** Date Received: **11/19/2024** Date Reported: **11/19/2024** Fasting: **Not Given**

Ordered Items: **NASH FibroSure(R) Plus**

General Comments & Additional Information

Clinical Info: NORMAL REPORT

Date Collected: **11/19/2024**

NASH FibroSure(R) Plus

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
NASH FibroSure(R)Plus Results: 01				
Fibrosis Score 01	0.06			0.00-0.21
Fibrosis Stage 01	F0 - No fibrosis			
. 01				
Steatosis Score 01	0.22			0.00-0.40
Steatosis Grade 01	S0 - No Steatosis (<5%)			
. 01				
NASH Score 01	0.00			0.00-0.25
NASH Grade 01	N0 - No NASH			
. 01				
Analysis: 01				
Methodology: 01	The analytes tested are performed by FibroSure-Specific methods. Not intended for use with other diagnostic considerations.			
Alpha 2-Macroglobulins, Qn 01	183		mg/dL	110-276
Haptoglobin 01	109		mg/dL	17-317
Apolipoprotein A-1 01	133		mg/dL	101-178
Bilirubin, Total 01	0.2		mg/dL	0.0-1.2
GGT 01	14		IU/L	0-65
ALT (SGPT) P5P 01	30		IU/L	0-55
AST (SGOT) P5P 01	19		IU/L	0-40
Cholesterol, Total 01	171		mg/dL	100-199
Glucose, Serum 01	99		mg/dL	70-99
Triglycerides 01	85		mg/dL	0-149
. 01				
Interpretations: 01	Quantitative results of 10 biochemicals in combination with age and gender, are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and Non-Alcoholic Steato-Hepatitis (NASH) (0.0-1.0, N0-N3), now known as Metabolic Dysfunction-Associated Steatohepatitis (MASH). The absence of			

©2024 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 336-436-2762

NASH FibroSure(R) Plus (Cont.)

steatosis (S<0.40) precludes the diagnosis of NASH/MASH.
Fibrosis marker: In a study of 171 Non-Alcoholic Fatty Liver Disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), patients where 23% had significant NAFLD/MASLD fibrosis (Metavir F2-F4) and 11% had cirrhosis by liver biopsy, a fibrosis result of >0.3 yielded a sensitivity of 83% and a specificity of 78% for the detection of significant fibrosis.[1]
Steatosis marker: In a population of 2997 patients, where 61% had significant steatosis (>=5%) on a liver biopsy, a steatosis score >0.4 had a sensitivity of 79% and a specificity of 50% for identification of significant steatosis.[2]
NASH/MASH marker: In a population of 1081 NAFLD/MASLD patients, where 51% had at least some NASH/MASH by liver biopsy, a prediction of NASH/MASH had a sensitivity of 72% for identifying NASH/MASH and a specificity of 71%.[3]

Fibrosis Scoring: [01]

```
     <=0.21 = Stage F0 - No fibrosis
0.21 - 0.27 = Stage F0 - F1
0.27 - 0.31 = Stage F1 - Portal fibrosis
0.31 - 0.48 = Stage F1 - F2
0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
0.72 - 0.74 = Stage F3 - F4
      >0.74 = Stage F4 - Cirrhosis
```

Steatosis Scoring [01]

```
     <=0.40 = S0  - No Steatosis (<5%)
0.40 - 0.55 = S1  - Mild Steatosis
                    (but Clinically Significant) (5-33%)
      >0.55 = S2S3- Moderate to Severe Steatosis
                    (Clinically Significant) (34-100%)
```

NASH Scoring [01]

```
     <=0.25 = N0 - No NASH/MASH
0.25 - 0.50 = N1 - Mild NASH/MASH
0.50 - 0.75 = N2 - Moderate NASH/MASH
      >0.75 = N3 - Severe NASH/MASH
```

Limitations: [01]

NASH FibroSure(R) Plus is recommended for patients with suspected non-alcoholic fatty liver disease, now known as Metabolic Dysfunction-Associated Steatotic Liver Disease or MASLD.
It is not recommended for patients with other liver diseases.
It is also not recommended in patients with Gilbert Disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra-hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Comment: [01]

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
For questions regarding this report please contact customer service at 1-800-788-9223.
References:
1. Ratziu V. et al. Diagnostic Value of Biochemical Markers (FibroTest) for the prediction of Liver Fibrosis in patients with

©2024 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 336-436-2762

Date Collected: **11/19/2024**

NASH FibroSure(R) Plus (Cont.)

Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology 2006; 6:6.
2. Poynard T. et al. The Diagnostic Performance of a Simplified Blood Test (SteatoTest-2) for the Prediction of Liver Steatosis. Eur J Gastroenterol Hepatol. 2019; 31:393-402.
3. Poynard T. et al. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Eur J Gastroenterol Hepatol. 2018 May; 30:569-577.

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Performing Labs
01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762

Patient Details
Sample Report, 550960

Phone:
Date of Birth: **01/01/1992**
Age: **32**
Sex: **Male**
Patient ID:
Alternate Patient ID:

Physician Details

LabCorp Test Master
458 South Main Street, BURLINGTON, NC, 27215

Phone: **999-999-9999**
Account Number: **90000999**
Physician ID:
NPI:

Specimen Details
Specimen ID: **324-988-9005-0**
Control ID:
Alternate Control Number:
Date Collected: **11/19/2024 0000 Local**
Date Received: **11/19/2024 0000 ET**
Date Entered: **11/19/2024 1228 ET**
Date Reported: **11/19/2024 1307 ET**

©2024 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 336-436-2762

Sample Report, 550960
Patient ID:
Specimen ID: **324-988-9006-0**

DOB: **01/01/1992**
Age: **32**
Sex: **Male**

Patient Report
Account Number: **90000999**
Ordering Physician:

labcorp

Date Collected: **11/19/2024** Date Received: **11/19/2024** Date Reported: **11/19/2024** Fasting: **Not Given**

Ordered Items: **NASH FibroSure(R) Plus**

General Comments & Additional Information

Clinical Info: ABNORMAL REPORT

Date Collected: **11/19/2024**

NASH FibroSure(R) Plus

	Test	Current Result and Flag		Previous Result and Date	Units	Reference Interval
	NASH FibroSure(R)Plus Results: 01					
▲	**Fibrosis Score** 01	**0.48**	**High**			0.00-0.21
	Fibrosis Stage 01	F1-F2				
	. 01					
▲	**Steatosis Score** 01	**0.61**	**High**			0.00-0.40
	Steatosis Grade 01					
		S2 - S3 Moderate to Severe Steatosis (Clinically Significant) (34-100%)				
	. 01					
▲	**NASH Score** 01	**0.83**	**High**			0.00-0.25
	NASH Grade 01					
		N3 - Severe NASH				
	. 01					
	Analysis: 01					
	Methodology: 01					
		The analytes tested are performed by FibroSure-Specific methods. Not intended for use with other diagnostic considerations.				
	Alpha 2-Macroglobulins, Qn 01	213			mg/dL	110-276
	Haptoglobin 01	78			mg/dL	17-317
	Apolipoprotein A-1 01	154			mg/dL	101-178
	Bilirubin, Total 01	0.9			mg/dL	0.0-1.2
▲	**GGT** 01	**227**	**High**		IU/L	0-65
▲	**ALT (SGPT) P5P** 01	**78**	**High**		IU/L	0-55
▲	**AST (SGOT) P5P** 01	**71**	**High**		IU/L	0-40
	Cholesterol, Total 01	147			mg/dL	100-199
▲	**Glucose, Serum** 01	**106**	**High**		mg/dL	70-99
▲	**Triglycerides** 01	**179**	**High**		mg/dL	0-149
	. 01					
	Interpretations: 01					
		Quantitative results of 10 biochemicals in combination with age and gender, are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and Non-Alcoholic Steato-Hepatitis (NASH) (0.0-1.0, N0-N3), now known as Metabolic Dysfunction-Associated Steatohepatitis (MASH). The absence of steatosis (S<0.40) precludes the diagnosis of NASH/MASH.				

©2024 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 336-436-2762

NASH FibroSure(R) Plus (Cont.)

Fibrosis marker: In a study of 171 Non-Alcoholic Fatty Liver Disease (NAFLD), now known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), patients where 23% had significant NAFLD/MASLD fibrosis (Metavir F2-F4) and 11% had cirrhosis by liver biopsy, a fibrosis result of >0.3 yielded a sensitivity of 83% and a specificity of 78% for the detection of significant fibrosis.[1]
Steatosis marker: In a population of 2997 patients, where 61% had significant steatosis (>=5%) on a liver biopsy, a steatosis score >0.4 had a sensitivity of 79% and a specificity of 50% for identification of significant steatosis.[2]
NASH/MASH marker: In a population of 1081 NAFLD/MASLD patients, where 51% had at least some NASH/MASH by liver biopsy, a prediction of NASH/MASH had a sensitivity of 72% for identifying NASH/MASH and a specificity of 71%.[3]

Fibrosis Scoring: [01]

```
     <=0.21 = Stage F0 - No fibrosis
0.21 - 0.27 = Stage F0 - F1
0.27 - 0.31 = Stage F1 - Portal fibrosis
0.31 - 0.48 = Stage F1 - F2
0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
0.72 - 0.74 = Stage F3 - F4
      >0.74 = Stage F4 - Cirrhosis
```

Steatosis Scoring [01]

```
     <=0.40 = S0  - No Steatosis (<5%)
0.40 - 0.55 = S1  - Mild Steatosis
                    (but Clinically Significant) (5-33%)
      >0.55 = S2S3- Moderate to Severe Steatosis
                    (Clinically Significant) (34-100%)
```

NASH Scoring [01]

```
     <=0.25 = N0 - No NASH/MASH
0.25 - 0.50 = N1 - Mild NASH/MASH
0.50 - 0.75 = N2 - Moderate NASH/MASH
      >0.75 = N3 - Severe NASH/MASH
```

Limitations: [01]

NASH FibroSure(R) Plus is recommended for patients with suspected non-alcoholic fatty liver disease, now known as Metabolic Dysfunction-Associated Steatotic Liver Disease or MASLD.
It is not recommended for patients with other liver diseases.
It is also not recommended in patients with Gilbert Disease, acute hemolysis, acute viral hepatitis, drug induced hepatitis, genetic liver disease, autoimmune hepatitis and/or extra-hepatic cholestasis. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis.

Comment: [01]

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
For questions regarding this report please contact customer service at 1-800-788-9223.
References:
1. Ratziu V. et al. Diagnostic Value of Biochemical Markers (FibroTest) for the prediction of Liver Fibrosis in patients with Non-Alcoholic Fatty Liver Disease. BMC Gastroenterology 2006; 6:6.

©2024 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 336-436-2762

Date Collected: **11/19/2024**

NASH FibroSure(R) Plus (Cont.)

2. Poynard T. et al. The Diagnostic Performance of a Simplified Blood Test (SteatoTest-2) for the Prediction of Liver Steatosis. Eur J Gastroenterol Hepatol. 2019; 31:393-402.
3. Poynard T. et al. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Eur J Gastroenterol Hepatol. 2018 May; 30:569-577.

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Performing Labs
01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
For inquiries, the physician may contact Branch: 800-222-7566 Lab: 336-436-2762

Patient Details
Sample Report, 550960

Phone:
Date of Birth: **01/01/1992**
Age: **32**
Sex: **Male**
Patient ID:
Alternate Patient ID:

Physician Details

LabCorp Test Master
458 South Main Street, BURLINGTON, NC, 27215

Phone: **999-999-9999**
Account Number: **90000999**
Physician ID:
NPI:

Specimen Details
Specimen ID: **324-988-9006-0**
Control ID:
Alternate Control Number:
Date Collected: **11/19/2024 0000 Local**
Date Received: **11/19/2024 0000 ET**
Date Entered: **11/19/2024 1229 ET**
Date Reported: **11/19/2024 1307 ET**

©2024 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version 2.00

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error please call 336-436-2762